# A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

> **NCT07393659** · PHASE3 · NOT_YET_RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 183 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Fostemsavir
- **DRUG:** Dolutegravir (DTG)/ Lamivudine (3TC)

## Key facts

- **NCT ID:** NCT07393659
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-08
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07393659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07393659, "A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07393659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*